Literature DB >> 31222866

The Proteome-Wide Potential for Reversible Covalency at Cysteine.

Kristine Senkane1, Ekaterina V Vinogradova1, Radu M Suciu1, Vincent M Crowley1, Balyn W Zaro1, J Michael Bradshaw2, Ken A Brameld2, Benjamin F Cravatt1.   

Abstract

Reversible covalency, achieved with, for instance, highly electron-deficient olefins, offers a compelling strategy to design chemical probes and drugs that benefit from the sustained target engagement afforded by irreversible compounds, while avoiding permanent protein modification. Reversible covalency has mainly been evaluated for cysteine residues in individual kinases and the broader potential for this strategy to engage cysteines across the proteome remains unexplored. Herein, we describe a mass-spectrometry-based platform that integrates gel filtration with activity-based protein profiling to assess cysteine residues across the human proteome for both irreversible and reversible interactions with small-molecule electrophiles. Using this method, we identify numerous cysteine residues from diverse protein classes that are reversibly engaged by cyanoacrylamide fragment electrophiles, revealing the broad potential for reversible covalency as a strategy for chemical-probe discovery.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  activity-based protein profiling; proteomics; reactive cysteines; reversible covalency; α-cyanoacrylamides

Year:  2019        PMID: 31222866      PMCID: PMC6684851          DOI: 10.1002/anie.201905829

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  36 in total

1.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Authors:  Douglas S Johnson; Eranthie Weerapana; Benjamin F Cravatt
Journal:  Future Med Chem       Date:  2010-06       Impact factor: 3.808

2.  A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding.

Authors:  Shintaro Nakayama; Ryo Atsumi; Hideo Takakusa; Yoshimasa Kobayashi; Atsushi Kurihara; Yoko Nagai; Daisuke Nakai; Osamu Okazaki
Journal:  Drug Metab Dispos       Date:  2009-06-01       Impact factor: 3.922

Review 3.  Covalent modifiers: an orthogonal approach to drug design.

Authors:  Michele H Potashman; Mark E Duggan
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

4.  Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide.

Authors:  D L Boger; H Sato; A E Lerner; M P Hedrick; R A Fecik; H Miyauchi; G D Wilkie; B J Austin; M P Patricelli; B F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

5.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

6.  Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.

Authors:  Srikanth Venkatraman; Stéphane L Bogen; Ashok Arasappan; Frank Bennett; Kevin Chen; Edwin Jao; Yi-Tsung Liu; Raymond Lovey; Siska Hendrata; Yuhua Huang; Weidong Pan; Tejal Parekh; Patrick Pinto; Veljko Popov; Russel Pike; Sumei Ruan; Bama Santhanam; Bancha Vibulbhan; Wanli Wu; Weiying Yang; Jianshe Kong; Xiang Liang; Jesse Wong; Rong Liu; Nancy Butkiewicz; Robert Chase; Andrea Hart; Sony Agrawal; Paul Ingravallo; John Pichardo; Rong Kong; Bahige Baroudy; Bruce Malcolm; Zhuyan Guo; Andrew Prongay; Vincent Madison; Lisa Broske; Xiaoming Cui; Kuo-Chi Cheng; Yunsheng Hsieh; Jean-Marc Brisson; Danial Prelusky; Walter Korfmacher; Ronald White; Susan Bogdanowich-Knipp; Anastasia Pavlovsky; Prudence Bradley; Anil K Saksena; Ashit Ganguly; John Piwinski; Viyyoor Girijavallabhan; F George Njoroge
Journal:  J Med Chem       Date:  2006-10-05       Impact factor: 7.446

7.  Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Authors:  David J Augeri; Jeffrey A Robl; David A Betebenner; David R Magnin; Ashish Khanna; James G Robertson; Aiying Wang; Ligaya M Simpkins; Prakash Taunk; Qi Huang; Song-Ping Han; Benoni Abboa-Offei; Michael Cap; Li Xin; Li Tao; Effie Tozzo; Gustav E Welzel; Donald M Egan; Jovita Marcinkeviciene; Shu Y Chang; Scott A Biller; Mark S Kirby; Rex A Parker; Lawrence G Hamann
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

Review 8.  Development of the proteasome inhibitor Velcade (Bortezomib).

Authors:  Julian Adams; Michael Kauffman
Journal:  Cancer Invest       Date:  2004       Impact factor: 2.176

9.  Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.

Authors:  Robert B Perni; Susan J Almquist; Randal A Byrn; Gurudatt Chandorkar; Pravin R Chaturvedi; Lawrence F Courtney; Caroline J Decker; Kirk Dinehart; Cynthia A Gates; Scott L Harbeson; Angela Heiser; Gururaj Kalkeri; Elaine Kolaczkowski; Kai Lin; Yu-Ping Luong; B Govinda Rao; William P Taylor; John A Thomson; Roger D Tung; Yunyi Wei; Ann D Kwong; Chao Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 10.  Vildagliptin: a new oral treatment for type 2 diabetes mellitus.

Authors:  Chantal Mathieu; Evy Degrande
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  6 in total

Review 1.  Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors.

Authors:  Giulia Bianco; David S Goodsell; Stefano Forli
Journal:  Trends Pharmacol Sci       Date:  2020-11-02       Impact factor: 14.819

2.  A quantitative thiol reactivity profiling platform to analyze redox and electrophile reactive cysteine proteomes.

Authors:  Ling Fu; Zongmin Li; Keke Liu; Caiping Tian; Jixiang He; Jingyang He; Fuchu He; Ping Xu; Jing Yang
Journal:  Nat Protoc       Date:  2020-07-20       Impact factor: 13.491

3.  A Chemical Proteomic Probe for the Mitochondrial Pyruvate Carrier Complex.

Authors:  Yu Yamashita; Ekaterina V Vinogradova; Xiaoyu Zhang; Radu M Suciu; Benjamin F Cravatt
Journal:  Angew Chem Int Ed Engl       Date:  2020-02-11       Impact factor: 15.336

4.  Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries.

Authors:  Miljan Kuljanin; Dylan C Mitchell; Devin K Schweppe; Ajami S Gikandi; David P Nusinow; Nathan J Bulloch; Ekaterina V Vinogradova; David L Wilson; Eric T Kool; Joseph D Mancias; Benjamin F Cravatt; Steven P Gygi
Journal:  Nat Biotechnol       Date:  2021-01-04       Impact factor: 54.908

5.  Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization.

Authors:  Vincent M Crowley; Marvin Thielert; Benjamin F Cravatt
Journal:  ACS Cent Sci       Date:  2021-04-05       Impact factor: 18.728

6.  Bardoxolone conjugation enables targeted protein degradation of BRD4.

Authors:  Bingqi Tong; Mai Luo; Yi Xie; Jessica N Spradlin; John A Tallarico; Jeffrey M McKenna; Markus Schirle; Thomas J Maimone; Daniel K Nomura
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.